. 2017 Mar 26;14(3):225–233. doi: 10.1177/1740774517700640
© The Author(s) 2017
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Figure 3.
Internal organizational barriers to implementing the FDA’s final rule.